A Phase 3 interventional study of GWP42003-P and Placebo in Seizures Associated With EMAS, sponsored by Jazz Pharmaceuticals. Terminated at 14 sites in 2 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing cannabidiol in Epilepsy — 2 open to participants now, 4 under way, 2 of them phase 3. Cannabidiol · Epilepsy.
Among the 20 studies testing cannabidiol in Epilepsy, this one is the 19th largest by enrollment, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 16th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 20 studies testing cannabidiol in Epilepsy are open now, in 2 countries. Recruiting first, the newest first:
UMC Utrecht · Sites in Netherlands
Ages 1–18
Elizabeth Donner · Sites in Canada
Ages 2–18
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 35 across the 20 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 9 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
17 studies in Epilepsy by Jazz Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 12 (71%) have results posted.
Among the 17 studies in Epilepsy by Jazz Pharmaceuticals, this one is the 16th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 3, and was the 17th registered.
Jazz Pharmaceuticals’s Epilepsy studies by the year they started, since 2007.
1 of the studies testing cannabidiol in Epilepsy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07668856Phase 3UMC UtrechtCannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing cannabidiol in Epilepsy, from their registry updates:
Among Jazz Pharmaceuticals’s 17 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary aim of Part A of the study to assess the efficacy and tolerability of GWP42003-P compared to placebo as an adjunctive treatment for children with Epilepsy with myoclonic-atonic seizures (EMAS) -associated seizures.
Part B of this study will be conducted to evaluate the long-term safety and tolerability of GWP42003-P in participants with EMAS.
The duration of study participation in Part A will be approximately 26 weeks, which includes a 1- to 3-week Screening Period, 4-week Baseline Observation Period, 14-week Dose Optimization Treatment Period, 10-day Taper Period, and a Safety Follow-up Period (4 weeks after end of taper visit). Participants will be randomized centrally in a 1:1 ratio to receive either GWP42003-P or matching placebo. Randomization will be stratified by clobazam use (on/off) and age of seizure onset (3 years of age and younger or older than 3 years of age). Upon completion of the double-blind phase (Part A), participants will have an option to continue in a 54-week open-label extension (Part B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
use by male and female participants should be consistent with Clinical Trial Facilitation Group (CTFG) guidelines and any applicable local regulations regarding the methods of contraception for those participating in clinical studies.
Part B only:
Exclusion Criteria:
Has significantly impaired hepatic function at the Screening visit (Visit 1) or prior to dosing, defined as any of the following:
This criterion can only be confirmed once the laboratory results are available.
Part B only:
Has significantly impaired hepatic function at Part A Visit 9, defined as any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be initiated on a dose of GWP42003-P 2.5 milligrams per kilogram (mg/kg) twice a day (BID) (5 mg/kg/day); after 1 week, the dose will be increased to 5 mg/kg BID (10 mg/kg/day). Dose escalation up to a maximum daily dosage of 20 mg/kg/day (in increments of 5 mg/kg/day \[2.5 mg/kg BID\] no more rapidly than every 7 days) may occur after Day 15 based on the investigator's assessment of efficacy, safety and tolerability.
Drug: GWP42003-P
Participants will receive the matching placebo.
Drug: Placebo
oral solution
Also known as: EPIDIOLEX, Cannabidiol, Cannabidiol oral solution (CBD-OS)
oral solution
Part A: Percent Change From Baseline in Epilepsy With Myoclonic-atonic Seizures (EMAS) Associated Seizure Frequency (Myoclonic-atonic, Atonic, Tonic, Clonic, or Tonic-clonic) Over the 14-week Treatment Period
Time frame: Baseline; up to 14 weeks
Part B: Number of Participants With Treatment-emergent Adverse Events
Time frame: up to Week 54
Part B: Number of Participants With Clinically Significant Vital Sign Values
Time frame: up to Week 50
Part B: Number of Participants With Clinically Significant Physical Examination Values
Time frame: up to Week 48
Part B: Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Values
Time frame: up to Week 48
Part B: Number of Participants With Clinically Significant Laboratory Test Values
Time frame: up to Week 48
Part B: Number of Participants With Changes in Tanner Staging
Time frame: up to Week 48
Part B: Number of Participants With a Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Ideation Scores
Time frame: up to Week 54
Part B: Number of Participants With a Change in the Number of Suicide Attempts Per C-SSRS Scores
Time frame: up to Week 54
Part A: Number of Participants Who Achieve ≥ 50% Reduction From Baseline in EMAS-associated Seizures Over the 14-week Treatment Period
Time frame: Baseline; up to 14 weeks
Part A: Total Seizure Frequency Over the 14-week Treatment Period
Time frame: Baseline; up to 14 weeks
Part A: Caregiver Global Impression of Change (CGIC) Score at Week 14
Time frame: Week 14
Part A: Physician Global Impression of Change (PGIC) Score at Week 14
Time frame: Week 14
Part A: Number of Participants Who Achieve ≥ 25%, ≥ 50%, ≥ 75%, and 100% Reduction From Baseline in Total Seizures Over the 14-week Treatment Period
Time frame: Baseline; up to 14 weeks
Part A: Change From Baseline in the Number of EMAS-associated Seizure-free Days Over the 14-week Treatment Period
Time frame: Baseline; up to 14 weeks
Part A: Number of Participants With at Least 25% and 50% Reduction From Baseline in the Number of Days Per Week With Myoclonic Seizures During the 14-week Treatment Period
Time frame: Baseline; up to 14 weeks
Part A: Time to Baseline Seizure Frequency
Time frame: up to 14 weeks
Part A: Number of Participants With Treatment-emergent Adverse Events
A TEAE is an adverse event that started or worsened in severity or seriousness following the first dose of the investigational medicinal product.
Time frame: From the time of informed consent signing up to 27 weeks.
Part A: Number of Participants With Clinically Significant Laboratory Test Values
Time frame: up to 27 weeks
Part A: Number of Participants With Clinically Significant Vital Sign Values
Time frame: up to 27 weeks
Part A: Number of Participants With Clinically Significant Physical Examination Values
Time frame: up to 27 weeks
Part A: Number of Participants With Clinically Significant 12-lead ECG Values
Time frame: up to 27 weeks
Part A: Number of Participants With Changes in Tanner Staging
Time frame: up to Day 99
Part A: Number of Participants With a Change in C-SSRS Ideation Scores
Time frame: up to 27 weeks
Part A: Number of Participants With a Change in the Number of Suicide Attempts Per C-SSRS Scores
Time frame: up to 27 weeks
Part B: Percent Change From Baseline in EMAS-associated Seizure Frequency (Myoclonic-atonic, Atonic, Tonic, Clonic, or Tonic-clonic) Over the 48-week Open-label Treatment Period
Time frame: Baseline; up to 48 weeks
Part B: Number of Participants Achieving ≥50% Reduction From Baseline in EMAS-associated Seizures Over the 48-week Open-label Treatment Period
Time frame: Baseline; up to 48 weeks
Part B: Total Seizure Frequency Over the 48-week Open-label Treatment Period
Time frame: up to Week 48
Part B: CGIC Score at Weeks 14, 24, and 48
Time frame: Weeks 14, 24, and 48
Part B: PGIC Score at Weeks 14, 24, and 48
Time frame: Weeks 14, 24, and 48
Part B: Number of Participants Who Achieve ≥ 25%, ≥ 50%, ≥ 75%, and 100% Reduction From Baseline in Total Seizures Over the 48-week Open-label Treatment Period
Time frame: Baseline; up to 48 weeks
Part B: Change From Baseline in the Number of EMAS-associated Seizure-free Days Over the 48-week Open-label Treatment Period
Time frame: Baseline; up to 48 weeks
Part B: Number of Participants With at Least 25% and 50% Reduction From Baseline in the Number of Days Per Week With Myoclonic Seizures During the 48-week Open-label Treatment Period
Time frame: Baseline; up to 48 weeks
Participants were screened for enrollment at 14 activated sites: 10 in the USA and 4 in Italy.
| Milestone | GWP42003-P | Placebo |
|---|---|---|
| Started | 1 | 1 |
| Completed | 0 | 0 |
| Not completed | 1 | 1 |
| Withdrew: Study terminated early | 1 | 1 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
A TEAE is an adverse event that started or worsened in severity or seriousness following the first dose of the investigational medicinal product.
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Part A: Number of Participants With Treatment-emergent Adverse Events | 1 | 1 |
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Part A: Number of Participants With Clinically Significant Laboratory Test Values | 0 | 0 |
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Part A: Number of Participants With Clinically Significant Vital Sign Values | 0 | 0 |
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Part A: Number of Participants With Clinically Significant Physical Examination Values | 0 | 0 |
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Part A: Number of Participants With Clinically Significant 12-lead ECG Values | 0 | 0 |
No measurements were reported for this outcome.
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Part A: Number of Participants With a Change in C-SSRS Ideation Scores | 0 | 0 |
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Part A: Number of Participants With a Change in the Number of Suicide Attempts Per C-SSRS Scores | 0 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over All treatment-emergent adverse events (TEAE) were collected from signing the informed consent up to approximately 27 weeks. No participants entered the open-label extension phase due to study termination.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003-P | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Placebo | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | GWP42003-P | Placebo |
|---|---|---|
| Gastroenteritis viralInfections and infestations | 1/1 | 0/1 |
| Event | GWP42003-P | Placebo |
|---|---|---|
| IrritabilityPsychiatric disorders | 1/1 | 1/1 |
| FatigueGeneral disorders | 1/1 | 0/1 |
| TachycardiaCardiac disorders | 1/1 | 0/1 |
| International normalised ratio increasedInvestigations | 1/1 | 0/1 |
| Blood triglyceridesInvestigations | 0/1 | 1/1 |
| Age, Categorical(Participants) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| <=18 years | 1 | 1 | 2 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 1 | 0 | 1 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Sep 2023, 10 months.
Results were first posted in Feb 2025, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol